Select Publications
Conference Papers
2017, 'Failure of antiretroviral therapy (ART) in Australian adults is mainly due to ART toxicity', in Antiviral Therapy, International Medical Press, Milan, Italy, presented at The 19th International Workshop on Co-morbidities and Adverse Drug Reaction in HIV, Milan, Italy, 23 October 2017 - 25 October 2017, http://dx.doi.org/10.26190/unsworks/27395
,2017, 'Polypharmacy of concomitant medications in HIV-infected Australian adults is common, and associated with adverse effects', in Antiviral Therapy, International Medical Press, Milan, Italy, presented at The 19th International Workshop on Co-morbidities and Adverse Drug Reaction in HIV, Milan, Italy, 23 October 2017 - 25 October 2017, http://dx.doi.org/10.26190/unsworks/27403
,2017, 'Socioeconomic and psychosocial factors are associated with suboptimal outcomes in HIV-infected adults: a case-control analysis', in Antiviral Therapy, International Medical Press, Milan, Italy, presented at The 19th International Workshop on Co-morbidities and Adverse Drug Reaction in HIV, Milan, Italy, 23 October 2017 - 25 October 2017, http://dx.doi.org/10.26190/unsworks/27399
,2016, 'Concomitant medication use in ART-experienced Australian adults: data from the PAART study', in Antiviral Therapy, International Medical Press, New York City, USA, presented at The 18th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV, New York City, USA, 12 September 2016 - 13 September 2016
,2014, 'Changes in bone mineral density and markers of bone turnover over 96 weeks after switching from tenofovir to raltegravir', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, PA, Philadelphia, pp. A35 - A35, presented at 16th International Workshop on Co-Morbidities and Adverse Drug Reaction in HIV, PA, Philadelphia, 06 October 2014 - 08 October 2014, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000354600300036&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2011, 'LOWER FAT MASS AND LOWER BONE FORMATION PREDICT GREATER BONE LOSS WITH TENOFOVIR IN HIV-INFECTED ADULTS', in OSTEOPOROSIS INTERNATIONAL, SPRINGER LONDON LTD, AUSTRALIA, Gold Coast, pp. S614 - S615, presented at IOF Regionals 2nd Asia-Pacific Osteoporosis and Bone Meeting / ANZBMS Annual Scientific Meeting held with the JSBMR, AUSTRALIA, Gold Coast, 04 September 2011 - 08 September 2011, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000309258200234&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2010, 'Macrophage inhibitory cytokine 1 (MIC-1) serum levels in the Lipodystrophy Case Definition Study', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, ENGLAND, London, pp. A28 - A29, presented at 12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, ENGLAND, London, 04 November 2010 - 06 November 2010, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000287431200046&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2010, 'Macrophage inhibitory cytokine 1 (MIC-1) serum levels in the Lipodystrophy Case Definition Study', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, ENGLAND, London, pp. A28 - A29, presented at 12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, ENGLAND, London, 04 November 2010 - 06 November 2010, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000287431500032&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2010, 'Predictors of limb fat changes in patients switched to tenofovir-emtricitabine or abacavir-lamivudine', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, ENGLAND, London, pp. A7 - A7, presented at 12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, ENGLAND, London, 04 November 2010 - 06 November 2010, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000287431200022&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2010, 'Predictors of limb fat changes in patients switched to tenofovir-emtricitabine or abacavir-lamivudine', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, ENGLAND, London, pp. A7 - A7, presented at 12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, ENGLAND, London, 04 November 2010 - 06 November 2010, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000287431500008&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2010, 'Glutamate excitotoxicity, cortical and subcortical neuronal damage as potential markers of HIV-associated neurocognitive disorder (HAND): A 1H-MRS and neuropsychological study', in JOURNAL OF NEUROVIROLOGY, TAYLOR & FRANCIS INC, ITALY, Milan, pp. 22 - 23, presented at 10th International Symposium on NeuroVirology, ITALY, Milan, 12 October 2010 - 16 October 2010, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000283409800048&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2009, 'Evaluation of adipose gene expression and mitochondrial DNA in healthy adults over a 6 week course of NRTI and/or PI treatment. Indications of divergent effects', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, PA, Philadelphia, pp. A10 - A11, presented at 11th International Workshop on AdverseDrug Reactions and Co-Morbidities in HIV, PA, Philadelphia, 26 October 2009 - 28 October 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000272060000029&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2008, 'Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy', in Circulation, http://dx.doi.org/10.1161/CIRCULATIONAHA.107.189624
,2008, 'Continuous antiretroviral therapy decreases bone mineral density: results from the SMART study', in Antiviral Therapy, Int Medical Press Ltd, London, England, pp. A26 - A26, presented at Antiviral Therapy
,2006, 'Metabolic syndrome in HIV-infected patients using IDF and ATPIII criteria: prevalence, discordance and clinical utility', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, CA, San Francisco, pp. L4 - L4, presented at 8th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, CA, San Francisco, 24 September 2006 - 26 September 2006, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000241975800023&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2006, 'Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV-infected adults', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, CA, San Francisco, pp. L4 - L4, presented at 8th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, CA, San Francisco, 24 September 2006 - 26 September 2006, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000241975800024&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2004, 'HIV drug adverse events: Selected highlights from the 15th International AIDS Conference', in HIV Clinical Trials, pp. 252 - 256, http://dx.doi.org/10.1310/43UQ-4UTE-4RDE-B5UY
,2003, 'HIV Lipodystrophy Case Definition Study Group. Impact of adiponectin, C-reactive protein and leptin on the HIV lipodystrophy case definition', in Antiviral Therapy, Int Medical Press Ltd, pp. 57 - 57
,2003, 'Impact of adiponectin, C-reactive protein and leptin on the HIV lipodystrophy case definition', in Antiviral Therapy, Int Medical Press Ltd, pp. L73 - L73
,2002, 'Disrupted expression of lipid transport genes in monocytes of individuals with HIV-associated lipodystrophy - an additional risk for cardiovascular disease?', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, CALIFORNIA, SAN DIEGO, pp. L8 - L9, presented at 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, CALIFORNIA, SAN DIEGO, 22 September 2002 - 25 September 2002, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000179501500023&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2002, 'Haematological changes in patients randomized to HAART regimens containing either zidovudine or stavudine', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, CALIFORNIA, SAN DIEGO, pp. L60 - L60, presented at 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, CALIFORNIA, SAN DIEGO, 22 September 2002 - 25 September 2002, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000179501500101&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2002, 'The effect of centralized body composition data analysis on an objective case definition of HIV lipodystrophy', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, CALIFORNIA, SAN DIEGO, pp. L53 - L53, presented at 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, CALIFORNIA, SAN DIEGO, 22 September 2002 - 25 September 2002, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000179501500089&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,1994, 'Primary infection with Zidovudine-resistant human immunodeficiency virus type 1 does not adverseley affect outcome at 1 year', in Journal of Infectious Diseases, University of Chicago Press, Chicago, IL, presented at International Workshop on HIV drug resistance, Hawaii
,1993, 'Roundtable discussion: Management issues in didanosine therapy', in Journal of Acquired Immune Deficiency Syndromes, pp. S51 - S55
,